Периооперативное применение Р-адреноблокаторов и риск сердечно-сосудистых осложнений: все ли вопросы решены?
Аннотация
Статья посвящена возможностям применения Р-адреноблокаторов в периоперационном периоде у больных с некардиальным хирургическим вмешательствам. Проанализированы результаты рандомизированных клинических испытаний POISE (2007) и DECREASE (1999-2009).
Об авторе
Ю. М. ЛопатинРоссия
Заведующий кафедрой кардиологии с функциональной диагностикой ФУВ; заведующий отделом ишемической болезни сердца
Список литературы
1. POISE Study Group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomized controlled trial. Lancet 2008; 371: 1839-47.
2. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007; 116: e418-99.
3. Yang H, Raymer K, Butler R, et al. The effects of perioperative beta-blockade: results of the Metoprolol after Vascular Surgery (MaVS) study, a randomized controlled trial. Am Heart J 2006; 152: 983-90.
4. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoingmajor non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. Br Med J 2006; 332: 1482.
5. Bangalore S, Wetterslev J, Pranesh Sh, et al. Perioperative p blockers in patients having non-cardiac surgery: a meta-analysis. Lancet 2008, D0I:10.1016/S0140-6736(08)61560-3.
6. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med 1999; 341: 1789-94.
7. Poldermans D, Boersma E, Bax JJ, et al., for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. Eur Heart J 2001; 22: 1353-8.
8. Poldermans D, Bax JJ, Schouten O, et al. for the Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echo Study Group. Should Major Vascular Surgery Be Delayed Because of Preoperative Cardiac Testing in Intermediate-Risk Patients Receiving Beta-Blocker Therapy With Tight Heart Rate Control? JACC 2006; 48: 964-9.
9. Poldermans D, Schouten O, Benner R, et al. Fluvastatin XL Use Is Associated With Improved Cardiac Outcome After Major Vascular Surgery. Results From A Randomized Placebo Controlled Trial: Decrease III. Circulation 2008; 118: S792.
10. Dunkelgrun M, Boersma E, Schouten O, et al. for The Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group Bisoprolol and Fluvastatin for the Reduction of Perioperative Cardiac Mortality and Myocardial Infarction in Intermediate-Risk Patients Undergoing Noncardiovascular Surgery. A Randomized Controlled Trial (DECREASE-IV). Ann Surg 2009; 249: 921-6.
Рецензия
Для цитирования:
Лопатин Ю.М. Периооперативное применение Р-адреноблокаторов и риск сердечно-сосудистых осложнений: все ли вопросы решены? Кардиоваскулярная терапия и профилактика. 2009;8(6):71-76.
For citation:
Lopatin Yu.M. Perioperative beta-adrenoblocker therapy and cardiovascular event risk: are all the problems solved? Cardiovascular Therapy and Prevention. 2009;8(6):71-76. (In Russ.)